Combinations of endocrine and biological agents: present status of therapeutic and presurgical investigations.

摘要: There is an increasing rationale to develop effective combinations of endocrine agents with novel therapeutics that target aberrant signal transduction pathways in estrogen receptor-positive breast cancer. Acquired resistance therapy associated increase peptide growth factor signaling results crosstalk activation receptor, and various inhibitors (STI) can these inhibit hormone-resistant growth. In experimental models hormone-sensitive cancer, STIs provide significantly greater inhibition than either alone, delaying the emergence resistance. are now several trials assessing efficacy tyrosine kinase tamoxifen-resistant/second-line setting, together five randomized phase II/III first-line setting. Similar work ongoing both farnesyltransferase mTOR antagonists where there strong preclinical data suggest additive or synergistic effects for combination tamoxifen deprivation therapies. More recently, presurgical studies biological primary end points being utilized as alternative approach investigate whether combined endocrine/STI a more strategy alone. This article reviews current status clinical this area well challenges lie ahead development therapeutic